Drug facts

Tirzepatide and diarrhea

By David Chen·Editor·Reviewed September 2026

How common it was¹

Table 1 of the label pools the two placebo-controlled obesity trials, Study 1 and Study 2, covering 2,519 adults treated for up to 72 weeks. The diarrhea row, by dose, with placebo beside it:

A footnote to the row says it counts both “diarrhea” and “frequent bowel movements.” About one participant in twelve reported it on placebo, so the part that belongs to the drug is the gap: about 11 percentage points at 5 mg, widening to 15 at 15 mg.

Unlike constipation, which falls from 17% to 11% as the dose goes up, diarrhea rises with every step. Only nausea (25–29%) was reported more often. Every reaction in the table, with its placebo rate →

When it happens, and how long it lasts¹

The label answers the timing question in one sentence of section 6.1: “The majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time.” It gives no duration in days or weeks, for an episode or for the pattern as a whole, and this page does not supply one.

The trial behind the label says the same thing in its own words.² The published SURMOUNT-1 abstract describes the most common adverse events as gastrointestinal, “mild to moderate in severity, occurring primarily during dose escalation.” That trial ran 72 weeks, including a 20-week dose-escalation period. What SURMOUNT-1 found →

The dose schedule itself is built around this.³ Section 2.1 starts everyone at 2.5 mg for four weeks and says to follow the escalation “to reduce the risk of gastrointestinal adverse reactions.” The steps are laid out in dosage and titration.

How many stopped because of it¹

Diarrhea sits inside a larger count. Across Studies 1 and 2, gastrointestinal adverse reactions of any kind were reported by 56% of participants at every tirzepatide dose, against 30% on placebo. Fewer stopped the drug over them: 1.9% at 5 mg, 3.3% at 10 mg and 4.3% at 15 mg, against 0.5% on placebo. The label adds that most people who stopped for any adverse reaction did so in the first few months, because of gastrointestinal reactions.

When diarrhea becomes a warning³

Two of the label’s warnings and precautions are about exactly this. They are not rated like the table above, and they are the part of this page that matters most.

Severe gastrointestinal adverse reactions (5.2)

Reported in 1.7%, 2.5% and 3.1% of participants at 5, 10 and 15 mg, against 1% on placebo. The label says the drug is not recommended in people with severe gastroparesis.

Acute kidney injury due to volume depletion (5.3)

Postmarketing reports of acute kidney injury, in some cases requiring hemodialysis. In the label’s words: “The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea.” It tells prescribers to monitor kidney function in patients reporting those reactions, especially while the dose is being started and raised.

In the trials themselves, section 6.1 records acute kidney injury in 0.5% of participants on tirzepatide against 0.2% on placebo, and notes that low blood pressure “also occurred in association with gastrointestinal adverse events and dehydration.”

The patient-facing version is in the Medication Guide, and it is an instruction rather than a number.⁴ It reads: “It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.”

What the Mounjaro label reports⁵

Mounjaro is the same molecule, approved for type 2 diabetes, and its label draws on different trials: a placebo pool of adults with type 2 diabetes. There, diarrhea was reported by 12% at 5 mg, 13% at 10 mg and 17% at 15 mg, against 9% on placebo. The populations differ, so the two rows are not interchangeable. The Mounjaro label uses the same timing sentence, that most nausea, vomiting and diarrhea came during dose escalation and decreased over time, and carries the same kidney-injury warning, numbered 5.5 there. How the two brands differ →

What none of this covers

Nothing here is medical advice, and this page deliberately suggests no remedy. Whether diarrhea needs managing, and how, is a question for the prescriber who wrote the prescription. See the medical disclaimer.